1
|
Sayın Kocakap DB, Kaygusuz S, Aksoy E, Şahin Ö, Baççıoğlu A, Ekici A, Kalpaklıoğlu AF, Ekici MS, Gül S, Kaçmaz B, Ayaşlıoğlu Açıkgöz E, Alyılmaz Bekmez S, Rouse BT, Azkur AK. Adverse effect of VEGFR-2 (rs1870377) polymorphism on the clinical course of COVID-19 in females and males in an age-dependent manner. Microbes Infect 2023; 25:105188. [PMID: 37499788 DOI: 10.1016/j.micinf.2023.105188] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 07/12/2023] [Accepted: 07/22/2023] [Indexed: 07/29/2023]
Abstract
The COVID-19 pandemic has affected people worldwide with varying clinical presentations ranging from mild to severe or fatal, and studies have found that age, gender, and some comorbidities can influence the severity of the disease. It would be valuable to have genetic markers that might help predict the likely outcome of infection. For this objective, genes encoding VEGFR-2 (rs1870377), CCR5Δ32 (rs333), and TLR3 (rs5743313) were analyzed for polymorphisms in the peripheral blood of 160 COVID-19 patients before COVID-19 vaccine was available in Türkiye. We observed that possession of the VEGFR-2 rs1870377 mutant allele increased the risk of severe/moderate disease in females and subjects ≥65 years of age, but was protective in males <65 years of age. Other significant results were that the CCR5Δ32 allele was protective against severe disease in subjects ≥65 years of age, while TLR3 rs5743313 polymorphism was found to be protective against severe/moderate illness in males <65 years of age. The VEGFR-2 rs1870377 mutant allele was a risk factor for severe/moderate disease, particularly in females over the age of 65. These findings suggest that genetic polymorphisms have an age- and sex-dependent influence on the severity of COVID-19, and the VEGFR-2 rs1870377 mutant allele could be a potential predictor of disease severity.
Collapse
Affiliation(s)
| | - Sedat Kaygusuz
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Emel Aksoy
- Department of Virology, Faculty of Veterinary Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Ömer Şahin
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Ayşe Baççıoğlu
- Department of Allergy and Immunology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye; Department of Pulmonary Diseases, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Aydanur Ekici
- Department of Pulmonary Diseases, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Ayşe Füsun Kalpaklıoğlu
- Department of Allergy and Immunology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye; Department of Pulmonary Diseases, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Mehmet Savaş Ekici
- Department of Pulmonary Diseases, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Serdar Gül
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Birgül Kaçmaz
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Ergin Ayaşlıoğlu Açıkgöz
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Sibel Alyılmaz Bekmez
- Department of Medical Genetics, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye
| | - Barry T Rouse
- College of Veterinary Medicine, University of Tennessee, Knoxville, TN, 37996, USA
| | - Ahmet Kürşat Azkur
- Department of Virology, Faculty of Veterinary Medicine, Kırıkkale University, Kırıkkale, Türkiye.
| |
Collapse
|
2
|
High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. Virol J 2023; 20:14. [PMID: 36698135 PMCID: PMC9875770 DOI: 10.1186/s12985-023-01974-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 01/20/2023] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020-2021. MATERIALS AND METHODS Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 - 10), 37 (IQR 35 - 38), 97 (IQR 95 - 100), and 187 (IQR 185 - 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. RESULTS Patients with high disease severity had higher mean log2 NAb titers at day 37 (1.58, 95% CI [0.34 -2.81]), 97 (2.07, 95% CI [0.53-3.62]) and 187 (2.49, 95% CI [0.20- 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [- 0.627 - 0.728]), expressed as log10 SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. CONCLUSIONS We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. TRIAL REGISTRATION The study is registered at https://clinicaltrials.gov/ (NCT05274373).
Collapse
|
3
|
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines (Basel) 2022; 10:vaccines10071071. [PMID: 35891235 PMCID: PMC9317843 DOI: 10.3390/vaccines10071071] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 06/28/2022] [Accepted: 07/02/2022] [Indexed: 12/23/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccinated with two doses of the BBIBP-CorV vaccine and to explore the boosting effect of the different vaccine platforms in BBIBP-CorV-primed healthy adults, including a viral vector vaccine (AZD122) and mRNA vaccines (BNT162b2 and mRNA-1273). The results showed that in the BBIBP-CorV prime group, the total receptor-binding domain (RBD) immunoglobulin (Ig) and anti-RBD IgG levels waned significantly at three months after receiving the second dose. However, after the booster, RBD-specific binding antibody levels increased. Neutralizing antibody measured by a surrogate neutralization test showed inhibition over 90% against the SARS-CoV-2 delta variant but less than 70% against the omicron variant after the third dose on day 28. All booster vaccines could induce the total IFN-ɣ T-cell response. The reactogenicity was acceptable and well-tolerated without serious adverse events. This study supports the administration of the third dose with either a viral vector or mRNA vaccine for BBIBP-CorV-primed individuals to stimulate antibody and T-cell responses.
Collapse
|
4
|
He L, Xu W, Zeng C, Li Y, Lin R, Xie X, Xia H, Tang S, Xu L, Chen C. Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients. J Infect 2022; 85:90-122. [PMID: 35461910 PMCID: PMC9021032 DOI: 10.1016/j.jinf.2022.04.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Accepted: 04/17/2022] [Indexed: 11/19/2022]
Affiliation(s)
- Lu He
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Wanzhou Xu
- Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Cheng Zeng
- Department of Orthopedics, Affiliated Hospital of Hebei University, Baoding, Hebei, China
| | - Ying Li
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Ren Lin
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Xiaojie Xie
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Hongmiao Xia
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Shiqi Tang
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Lijuan Xu
- Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
| | - Changzheng Chen
- Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
| |
Collapse
|